Veradermics, Incorporated (MANE) Investor Relations Documents

Veradermics, Incorporated (MANE) investor relations documents from the company's IR site: 3 presentations, 16 press releases; latest deck 2026-07-14. Read in-app with summaries. First-party data.

Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females Presentation: Veradermics' Study ‘207’ Phase 2 open-label trial of VDPHL01 in females met efficacy endpoints, showing rapid hair growth and supporting a 1H27 registration readout.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseVeradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-07-17Press releaseVeradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair
2026-07-15Press releaseVeradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead
2026-07-14PresentationStudy ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females Presentation
2026-07-14Press releaseVeradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mil
2026-06-09PresentationCorporate Presentation
2026-05-28Press releaseVeradermics to Present at Upcoming June Investor Conferences
2026-05-27Press releaseVeradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Con
2026-05-14Press releaseVeradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
2026-05-12Press releaseVeradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-04-29Press releaseVeradermics Announces Pricing of Upsized Public Offering and Private Placement
2026-04-27Earnings deckStudy 302 Phase 2/3 Topline Results Presentation
2026-04-27Press releaseVeradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial
2026-04-27Press releaseVeradermics Announces Launch of Public Offering
2026-04-26Press releaseVeradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-
2026-03-30Press releaseVeradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Upd
2026-03-18Press releaseVeradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy o
2026-03-03Press releaseVeradermics to Participate in Upcoming March Investor Conferences
2026-02-09Press releaseVeradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
2026-02-04Regulatory report0000876661-26-000084.pdf

MANE overview · MANE earnings · MANE financials · MANE KPIs · MANE documents · MANE ownership · MANE peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.